These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 26904396)

  • 1. Direct anti-HCV agents.
    Zhang X
    Acta Pharm Sin B; 2016 Jan; 6(1):26-31. PubMed ID: 26904396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction.
    Geddawy A; Ibrahim YF; Elbahie NM; Ibrahim MA
    J Transl Int Med; 2017 Mar; 5(1):8-17. PubMed ID: 28680834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections.
    Izhari MA
    Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
    De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
    J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents.
    Kalaghatgi P; Sikorski AM; Knops E; Rupp D; Sierra S; Heger E; Neumann-Fraune M; Beggel B; Walker A; Timm J; Walter H; Obermeier M; Kaiser R; Bartenschlager R; Lengauer T
    PLoS One; 2016; 11(5):e0155869. PubMed ID: 27196673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
    Yu ML
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1436-1442. PubMed ID: 28124463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral therapies for chronic hepatitis C virus infection with cirrhosis.
    Nakamoto S; Kanda T; Shirasawa H; Yokosuka O
    World J Hepatol; 2015 May; 7(8):1133-41. PubMed ID: 26052402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Grazoprevir/elbasvir combination therapy for HCV infection.
    Vallet-Pichard A; Pol S
    Therap Adv Gastroenterol; 2017 Jan; 10(1):155-167. PubMed ID: 28286567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical genetics-based development of small molecules targeting hepatitis C virus.
    Jin G; Lee J; Lee K
    Arch Pharm Res; 2017 Sep; 40(9):1021-1036. PubMed ID: 28856597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hepatitis C: perspectives.
    Pol S; Corouge M
    Med Mal Infect; 2014 Oct; 44(10):449-54. PubMed ID: 25174659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection.
    Kanda T; Nakamoto S; Nakamura M; Jiang X; Miyamura T; Wu S; Yokosuka O
    J Clin Transl Hepatol; 2014 Mar; 2(1):1-6. PubMed ID: 26356295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
    Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
    Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid progression of antiviral treatments of chronic hepatitis C virus infection.
    Pol S; Corouge M; Mallet V; Sogni P
    Minerva Gastroenterol Dietol; 2013 Jun; 59(2):161-72. PubMed ID: 23831907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current race in the development of DAAs (direct-acting antivirals) against HCV.
    De Clercq E
    Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy.
    Das D; Pandya M
    Mini Rev Med Chem; 2018; 18(7):584-596. PubMed ID: 28901852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-drug interactions during antiviral therapy for chronic hepatitis C.
    Kiser JJ; Burton JR; Everson GT
    Nat Rev Gastroenterol Hepatol; 2013 Oct; 10(10):596-606. PubMed ID: 23817323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of hepatitis C: current status and perspectives].
    Pol S; Corouge M
    Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic hepatitis C in patients with HIV/HCV coinfection.
    Coppola N; Martini S; Pisaturo M; Sagnelli C; Filippini P; Sagnelli E
    World J Virol; 2015 Feb; 4(1):1-12. PubMed ID: 25674512
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.